XOMA Strengthens Leadership Team with Appointments of Chief Business Officer and General Counsel
January 08 2018 - 7:00AM
XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery,
development and licensing of therapeutic antibodies, today
announced the appointments of Dee Datta, Ph.D., as Chief Business
Officer and Danny Hart as Vice President, General Counsel. Dr.
Datta and Mr. Hart will report to XOMA’s Chief Executive Officer,
Jim Neal.
“Dee and Danny bring significant value to XOMA’s team as we
continue to execute on our transformation into a royalty
aggregator,” stated Jim Neal, Chief Executive Officer of XOMA.
“Their expertise and experience will be invaluable as we expand our
portfolio to drive revenue growth and create value for
shareholders. We are excited they have chosen to join our
team.”
Dr. Datta brings extensive leadership experience in business
development, alternative financing strategies and corporate
strategy. Prior to joining XOMA, Dr. Datta served as Vice President
of Corporate Development at Forty Seven, Inc., where she managed
business development, strategy and transactions, company financing
and investor relations. Previously, Dr. Datta was the Senior
Director of Business Development at XOMA. During her time at XOMA,
she successfully closed multiple transactions, including licensing
deals with Novartis and Novo Nordisk. Earlier in her career, Dr.
Datta was a venture capitalist at The Column Group and Longitude
Capital. As an investor, she has experience in alternative
financing strategies, such as royalty monetization, in addition to
formation and management of portfolio companies. Dr. Datta received
her Ph.D. from California Institute of Technology and M.B.A. from
Stanford University Graduate School of Business.
Mr. Hart brings a breadth of knowledge in corporate governance,
securities law compliance, and mergers and acquisitions. Prior to
joining XOMA, Mr. Hart was Vice President, Business Development at
PDL BioPharma, Inc. (PDL), where he focused on the company’s
investment activity by identifying, evaluating, structuring and
completing alternative, non-dilutive financing investments
(structured debt, synthetic royalty, royalty monetization) for
late-stage pharmaceutical, device and diagnostic companies. Mr.
Hart also served in various legal capacities at PDL, where he led
PDL’s transactional efforts, completing over $1 billion in
investment transactions during his tenure at PDL. Previously, Mr.
Hart was an associate with Hogan & Hartson LLP (now Hogan
Lovells US LLP), where his practice focused on securities,
corporate governance and mergers and acquisitions, and he started
his legal career at Skadden, Arps, Slate, Meagher & Flom LLP.
Mr. Hart received his J.D. from Vanderbilt Law School and B.A. from
the University of Washington in Seattle.
About XOMA Corporation
XOMA has built a portfolio of over two dozen products that are
licensed to and being developed by other biotech and pharmaceutical
companies. The Company’s portfolio of fully-funded programs spans
multiple stages of the drug development process and across various
therapeutic areas. Many of these licenses are the result of the
Company's pioneering efforts in the discovery and development of
antibody therapeutics. XOMA’s license portfolio has the potential
to generate significant milestone payments and royalty revenue in
the future. For more information, visit www.xoma.com.
Forward-Looking Statements
Certain statements contained in this press release are
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934, including statements regarding the potential of XOMA’s
portfolio of partnered programs and licensed technologies
generating substantial milestone and royalty proceeds over time.
These statements are based on assumptions that may not prove
accurate, and actual results could differ materially from those
anticipated due to certain risks inherent in the biotechnology
industry and for companies engaged in the development of new
products in a regulated market. Potential risks to XOMA meeting
these expectations are described in more detail in XOMA's most
recent filing on Form 10-K and in other SEC filings. Consider such
risks carefully when considering XOMA's prospects. Any
forward-looking statement in this press release represents XOMA's
views only as of the date of this press release and should not be
relied upon as representing its views as of any subsequent date.
XOMA disclaims any obligation to update any forward-looking
statement, except as required by applicable law.
Investor contact:Luke HeaglePure
Communications+1 910-726-1372lheagle@purecommunications.com
Media contact:Julie NormartPure
Communications+1 415-946-1087jnormart@purecommunications.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024